Recruiting
Phase 1
Phase 2

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia

Sponsor:

Janssen Research & Development, LLC

Code:

NCT04811560

Conditions

Acute Leukemias

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Bleximenib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information